Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
The latest update is out from Futura Medical ( (GB:FUM) ).
Futura Medical has reported a successful year with revenue and profit after tax surpassing market expectations for FY24, largely due to the global launch of Eroxon, their lead product for erectile dysfunction. Despite a promising start, the company anticipates lower-than-expected US sales for FY25, attributing this to initial consumer uptake challenges and slower expansion in certain markets, which will likely result in reduced revenue and profits, yet remains confident in future growth potential due to robust retailer support and strategic marketing adjustments.
More about Futura Medical
Futura Medical plc is a consumer healthcare company specializing in the development and commercialization of innovative sexual health products, such as Eroxon, which is clinically proven. Their core focus is on topically delivered gel formulations aimed at addressing prevalent sexual health issues affecting both men and women globally.
YTD Price Performance: -2.05%
Average Trading Volume: 534,177
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £94.04M
For an in-depth examination of FUM stock, go to TipRanks’ Stock Analysis page.
